NEW YORK, Dec. 1, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17 ...
LOS ANGELES, CA / ACCESSWIRE / December 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
On Friday, Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.47 which represents a slight increase of $0.07 or 1.59% from the prior close of $4.4. The stock opened at $4.44 and ...
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Fox, MD, FACS, Director of Vascular Surgery at the University of Maryland Capital Region, a clinical investigator in the Humacyte V005 trauma clinical trial. "The ATEV is perfectly sized to treat most ...
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has be ...
5d
If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your ...
Benchmark analyst Bruce Jackson maintained a Buy rating on Humacyte (HUMA) with a price target of $15.00, suggesting a significant upside for the company’s stock. Humacyte shares closed at $5.39 ...
DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...
Humacyte HUMA will release its quarterly earnings report on Friday, 2024-11-08. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Humacyte to report an earnings ...
LOS ANGELES, Nov. 29, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback